Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2005

View Archived Issues

LXR agonist induces regression of atherosclerotic lesions in preclinical model

Group III mGluRs agonist shows promise in the treatment of neuropathic pain

Metabasis Therapeutics extends and expands Merck & Co. hepatitis C collaboration

MT-100 recommended for approval in U.K.

Encouraging findings from phase I studies of GRC-3886

Endpoints met in first stage of CoFactor phase II colorectal cancer study

GlycoGenesys advances development of GCS-100LE

Alnylam initiates program to develop RNAi therapeutics for spinal cord injury

UroVysion DNA probe assay approved

Millennium and UCB Pharma collaborate on antibody inflammation programs

Nektar and Zelos Therapeutics collaborate on inhaleable Ostabolin-C

Positive phase I/II results of AVR-118 in cachectic patients with AIDS

Enrollment open in phase Ib/II study of ARQ-501 with gemcitabine

New phase I study for PYY3-36 Nasal Spray for obesity

E1-I.N.T. cleared to enter clinical trials for type 2 diabetes

Viventia completes enrollment in second phase I study of Proxinium

AMD-3100 phase III program opens enrollment

Treatment begins in phase II study of HER-2 Protein AutoVac

New clinical data on estrogen therapy and the risk of gallbladder disease in postmenopausal women

Low recurrence of ulcer bleeding found with an aspirin plus esomeprazole regimen

Deoxyhypusine synthase inhibition as a new strategy against HIV/News in Context

New opioid analgesics described in a Euroceltique patent

Zentaris researchers disclose agents for proliferative disorders

Phosphodiesterase inhibitors prepared and tested at GlaxoSmithKline

New therapies for Parkinson's disease claimed by Roche

Merck reports novel prostaglandin D2 antagonists

COX-2 inhibitors discovered by Merck team

Merck presents new DPP-IV inhibitors with potential use in diabetes

Sulfasalazine promotes recovery from liver fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...